ASC-CM Secretome Therapy for ALS
Our inaugural engagement — partnering with Dr. Chandler Walker at the IU School of Medicine to build the commercialization framework for a novel neuroprotective biologic.
Dr. Chandler L. Walker
Associate Professor, IU School of Dentistry · Adjunct Associate Professor of Anatomy, Cell Biology & Physiology · Assistant Professor, Biomedical & Applied SciencesDr. Walker's research demonstrates that repeated administration of adipose-derived stem cell conditioned media (ASC-CM) delays symptom onset and preserves neuromuscular junction integrity in the SOD1 mouse model of ALS.
These findings support ASC-CM's potential as a scalable, cell-free biologic capable of delivering neurotrophic and immunomodulatory effects without the logistical burdens of live stem cell transplantation — a significant advantage for manufacturing and regulatory strategy.
JBV's role is to refine the translational narrative around this therapy and build the communication tools, commercial frameworks, and external partnerships required to position ASC-CM for next-stage development and venture funding.
JBV is actively helping to raise $1.5 million for the additional toxicology study required before Dr. Walker's team can submit the IND application to the FDA. We are targeting a combination of grant funding, venture capital, and pharma industry partnerships to close this critical financing gap and advance ASC-CM toward first-in-human trials.
